Type I Diabetes clinical trials

Explore recruiting type i diabetes clinical trials.

Recruiting type i diabetes studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Type I Diabetes trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

LAMAinDiab - lisdexamphetamine vs methylphenidate for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial.

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A research study investigating the effect of NNC0497-0040 in healthy participants, participants with overweight or obesity, and participants with type 1 diabetes with overweight or obesity.

Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

First-in-human safety study of pancreatic islet transplantation without immune suppression in adult subjects with type 1 diabetes

Sweden

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults with Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype

Germany, Spain, Czechia, Netherlands, Hungary, Estonia +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE)

Sweden, Belgium, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A research study of a new medicine NNC0363-1063 in healthy participants and participants with type 1 diabetes

Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Type I Diabetes trials by city

Type I Diabetes in Toronto Type I Diabetes in Vancouver Type I Diabetes in Montreal Type I Diabetes in Calgary Type I Diabetes in Edmonton Type I Diabetes in Ottawa Type I Diabetes in Winnipeg Type I Diabetes in Quebec City Type I Diabetes in Hamilton Type I Diabetes in Kitchener Type I Diabetes in London Type I Diabetes in Halifax Type I Diabetes in New York Type I Diabetes in Los Angeles Type I Diabetes in Chicago Type I Diabetes in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease